Safety Study of Anti-IgE Immunotherapy in Allergic Patients
NCT00439621
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
42
Enrollment
INDUSTRY
Sponsor class
Conditions
Allergy
Interventions
BIOLOGICAL:
RP 01
Sponsor
Resistentia Pharmaceuticals AB